Torna ai risultati
Scheda bibliografica · Consultazione e accesso
Revista científica

Dmd and beyond: molecular modifiers that alter disease progression in patients with dystrophinopathy

Mazzanti, Chiara et al · Fundación Revista Medicina · 2022

Testo completo ad accesso aperto
Lettura rapida. Controlla i dati essenziali della risorsa e accedi al contenuto con il pulsante principale. La scheda mostra solo le informazioni necessarie per identificare, citare e aprire l’opera.

Accesso alla risorsa

Elegí el proveedor desde el que querés acceder.

CONICET Digital CONICET Digital OAI-PMH
Entrar por CONICET Digital
Accesso principale

Testo completo ad accesso aperto

Texto completo identificado como acceso abierto.
Apri testo
Otras opciones de acceso Elegí el proveedor disponible para esta ficha.
CONICET Digital OAI-PMH
Acceder por CONICET Digital OAI-PMH
eLibro Cátedra · Actualización completa julio 2026 eLibro Cátedra
Acceder por eLibro Cátedra · Actualización completa julio 2026

Altre opzioni disponibili

Se la risorsa è presente su più piattaforme, puoi scegliere dove aprirla.

CONICET Digital OAI-PMH Accesso disponibile
Apri
eLibro Cátedra · Actualización completa julio 2026 eLibro Cátedra Accesso disponibile
Apri

Riepilogo

Descripción general del contenido del recurso.

Duchenne muscular dystrophy (DMD) is one of the most frequent and severe presentation of pediatric muscular dystrophies. There is great variability in the progression of the disease between DMD patients, even affected males with the same mutation lose the ability to walk at very different ages. Recent studies point to different SNPs in SPP1, LTBP4, CD40 and ACTN3 as the cause of these phenotypic variations. This work focused on characterizing these genetic modifiers in the DMD/DMB argentine cohort and validating their prognostic value. Of a total of 60 DMD patients, two groups of extreme phenotypes were created. The first contained 30 patients with loss of ambulation before the age of 11 (severe phenotype), while the second contained 24 patients who continue walking or who have lost ambulation at ages equal to or greater than 15 (mild phenotype). Previously reported SNPs in the SPP1, LTBP4, CD40 and ACTN3 genes were evaluated by PCR-Sanger sequencing. The chi square test was performed to determine that the differences between the severe and mild groups were significant. ACTN3 SNP showed a significant difference between both groups. The results of this work would indicate that the SNP rs1815739 in ACTN3 is a modifier for DMD progression, while the SNPs proposed in the other genes couldn´t be associated. The importance of the analysis of these molecular modifiers lies in understanding the origin of the variability of clinical manifestations among individuals affected with these monogenic disorders. This will allow, on the one hand, to improve the design and evaluation of clinical trials, as well as improve patient prognosis and personalization of treatments, opening the way to the development of new molecular targets for gene therapy. Fil: Mazzanti, Chiara. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina Fil: Carcione, María Micaela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina

Come citare

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Mazzanti, C. E. A. (2022). Dmd and beyond: molecular modifiers that alter disease progression in patients with dystrophinopathy. http://hdl.handle.net/11336/247573

MLA

Mazzanti, Chiara et al. "Dmd and beyond: molecular modifiers that alter disease progression in patients with dystrophinopathy." 2022. http://hdl.handle.net/11336/247573.

Chicago

Mazzanti, Chiara et al. 2022. "Dmd and beyond: molecular modifiers that alter disease progression in patients with dystrophinopathy.". http://hdl.handle.net/11336/247573.

Harvard

Mazzanti, C. E. A. 2022, Dmd and beyond: molecular modifiers that alter disease progression in patients with dystrophinopathy, Fundación Revista Medicina, available at: http://hdl.handle.net/11336/247573 [Accessed 8 Aug. 2026].

Condividi e stampa

Salva la scheda, copia il link permanente o stampala in PDF.

Esporta riferimento

Esporta il record nei formati più comuni per usarlo con un gestore bibliografico.

Dettagli della risorsa

Informazioni bibliografiche utili per verificare che sia il materiale corretto.

Titolo
Dmd and beyond: molecular modifiers that alter disease progression in patients with dystrophinopathy
Autore / collaboratori
Mazzanti, Chiara et al
Editore
Fundación Revista Medicina
Anno di pubblicazione
2022
ISSN
0025-7680
ISSN
0025-7680
Lingua
Inglés

Soggetti

Esplora risorse correlate a partire da questi soggetti.

Copiato